rivadia 2,5 mg filmovertrukne tabletter
towa pharmaceutical europe, s.l. - rivaroxaban - filmovertrukne tabletter - 2,5 mg
clarithromycin "actavis" 500 mg depottabletter
actavis group ptc ehf. - clarithromycincitrat - depottabletter - 500 mg
clarithromycin "alternova" 500 mg pulver til infusionsvæske, opløsning
alternova a/s - clarithromycin - pulver til infusionsvæske, opløsning - 500 mg
clarithromycin "hexal" 500 mg filmovertrukne tabletter
hexal a/s - clarithromycin - filmovertrukne tabletter - 500 mg
clarithromycin "krka" 250 mg filmovertrukne tabletter
krka d.d. novo mesto - clarithromycin - filmovertrukne tabletter - 250 mg
clarithromycin "stada" 250 mg filmovertrukne tabletter
stada arzneimittel ag - clarithromycin - filmovertrukne tabletter - 250 mg
clarithromycin "teva" 250 mg filmovertrukne tabletter
teva b.v. - clarithromycin - filmovertrukne tabletter - 250 mg
klacid 25 mg/ml granulat til oral suspension
viatris aps - clarithromycin - granulat til oral suspension - 25 mg/ml
klacid uno 500 mg depottabletter
viatris aps - clarithromycin - depottabletter - 500 mg
rivaroxaban accord
accord healthcare s.l.u. - rivaroxaban - acute coronary syndrome; coronary artery disease; peripheral arterial disease; venous thromboembolism; stroke; atrial fibrillation; pulmonary embolism - antitrombotiske midler - forebyggelse af venøs tromboembolisme (vte) hos voksne patienter, der gennemgår valgfri hofte- eller knæskifteoperation. behandling af dyb venøs trombose (dvt) og lungeemboli (pe), og forebyggelse af recidiverende dvt og pe i voksne. (see section 4. 4 for haemodynamically unstable pe patients. behandling af dyb venøs trombose (dvt) og lungeemboli (pe), og forebyggelse af recidiverende dvt og pe i voksne. (see section 4. 4 for haemodynamically ustabile pe patienter). adultsprevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. behandling af dyb venøs trombose (dvt) og lungeemboli (pe), og forebyggelse af recidiverende dvt og pe i voksne. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. rivaroxaban accord, co administered with acetylsalicylic acid (asa) alone or with asa plus ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers (see sections 4. 3, 4. 4 og 5. rivaroxaban accord, co administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. behandling af dyb venøs trombose (dvt) og lungeemboli (pe), og forebyggelse af recidiverende dvt og pe i voksne. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.